Method of Treatment Claims That Incorporate Inventive Steps Are Not Invalid Under 35 U.S.C. § 101

Sep 1, 2016

Reading Time : 2 min

Vanda’s claims at issue were directed to methods of treating patients with schizophrenia or a schizoaffective disorder by administering a particular dose of the compound iloperidone, where the correct dose is determined based on the results of genetic testing. During development of iloperidone, Vanda discovered that patients with a certain genetic mutation in an enzyme called CYP2D6 poorly metabolize iloperidone, and those patients therefore have increased concentrations of iloperidone in their blood. Increased concentrations of iloperidone can lead to serious side effects, including a type of abnormal heart rhythm that can result in sudden death. Vanda’s method claims are based on this discovery and require that genetic testing be performed on a patient before the patient is administered iloperidone to determine whether the patient has a genetic mutation in CYP2D6. If the patient does not have the genetic mutation, the patient receives the maximum dose of the drug. If the patient does have the genetic mutation and is thus a poor metabolizer of the drug, the dose of the drug is reduced by half (thereby reducing the likelihood of experiencing serious side effects).

Roxane argued that Vanda’s method claims are directed to patent-ineligible subject matter because the claims cover a law of nature applied in a routine and conventional way. To decide this issue, the court applied the two-step analysis of Alice Corp. Pty. v. CLS Bank Int’l, 134 S. Ct. 2347 (2014). First, the court determined whether the asserted method claims depend on laws of nature. According to the court, the claims depend on the natural relationship among iloperidone, mutations in CYP2D6 that cause poor metabolism of iloperidone and raise the concentration of the drug in the blood, and the effect of the increased concentration of iloperidone on normal heart rhythms. Thus, the court found that the claims do depend on laws of nature. Second, the court analyzed whether the claims incorporate some additional non-routine or non-conventional step to transform the nature of the claims into patent eligible subject matter. Vanda’s method claims require genetic testing to determine whether a patient has a CYP2D6 mutation, and, based on the results of that testing, determining the appropriate dose of the administered drug. Relying on competing expert testimony, the court found that Roxane failed to prove that the genetic testing required by the claims and the results of that testing were routine or conventional. The court also noted that it found persuasive that the step of adjusting the dose of the drug does not apply to all patients, but only to those with the genetic mutation, such that the dosage step requires applying genetic testing in a highly specified way. The court thus concluded that the combination of elements recited in the claims is sufficient to ensure that the claims are directed to significantly more than just a natural law.

Vanda Pharma. Inc. v. Roxane Labs, Inc., 13-1973, 14-757-GMS (D. Del. August 25, 2016) (Judge Sleet).

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.